ARF as an onco-suppressor impedes carcinogenesis not only through interfering with cell proliferation and induction of apoptosis, but also via affecting other cancer-promoting processes such as angiogenesis (Kawagishi et al., 2010; Ulanet and Hanahan, 2010). The gene discussed is CDKN2A; the disease is cancer.